In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies.

Palleis, Carla; Sauerbeck, Julia; Beyer, Leonie; Harris, Stefanie; Schmitt, Julia; Morenas-Rodriguez, Estrella; Finze, Anika; Nitschmann, Alexander; Ruch-Rubinstein, Francois; Eckenweber, Florian; Biechele, Gloria; Blume, Tanja; Shi, Yuan; Weidinger, Endy; Prix, Catharina; Bötzel, Kai; Danek, Adrian; Rauchmann, Boris-Stephan; Stöcklein, Sophia; Lindner, Simon; ... (2020). In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies. (In Press). Movement disorders Wiley-Blackwell 10.1002/mds.28395

[img]
Preview
Text
mds.28395.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (1MB) | Preview

BACKGROUND

Neuroinflammation has received growing interest as a therapeutic target in neurodegenerative disorders, including 4-repeat tauopathies.

OBJECTIVES

The aim of this cross-sectional study was to investigate 18 kDa translocator protein positron emission tomography (PET) as a biomarker for microglial activation in the 4-repeat tauopathies corticobasal degeneration and progressive supranuclear palsy.

METHODS

Specific binding of the 18 kDa translocator protein tracer 18 F-GE-180 was determined by serial PET during pharmacological depletion of microglia in a 4-repeat tau mouse model. The 18 kDa translocator protein PET was performed in 30 patients with corticobasal syndrome (68 ± 9 years, 16 women) and 14 patients with progressive supranuclear palsy (69 ± 9 years, 8 women), and 13 control subjects (70 ± 7 years, 7 women). Group comparisons and associations with parameters of disease progression were assessed by region-based and voxel-wise analyses.

RESULTS

Tracer binding was significantly reduced after pharmacological depletion of microglia in 4-repeat tau mice. Elevated 18 kDa translocator protein labeling was observed in the subcortical brain areas of patients with corticobasal syndrome and progressive supranuclear palsy when compared with controls and was most pronounced in the globus pallidus internus, whereas only patients with corticobasal syndrome showed additionally elevated tracer binding in motor and supplemental motor areas. The 18 kDa translocator protein labeling was not correlated with parameters of disease progression in corticobasal syndrome and progressive supranuclear palsy but allowed sensitive detection in patients with 4-repeat tauopathies by a multiregion classifier.

CONCLUSIONS

Our data indicate that 18 F-GE-180 PET detects microglial activation in the brain of patients with 4-repeat tauopathy, fitting to predilection sites of the phenotype. The 18 kDa translocator protein PET has a potential for monitoring neuroinflammation in 4-repeat tauopathies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Rominger, Axel Oliver

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0885-3185

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Sabine Lanz

Date Deposited:

28 Dec 2020 08:38

Last Modified:

13 Mar 2021 18:29

Publisher DOI:

10.1002/mds.28395

PubMed ID:

33245166

Uncontrolled Keywords:

corticobasal syndrome four-repeat tauopathies progressive supranuclear palsy sTREM2 translocator protein

BORIS DOI:

10.48350/149387

URI:

https://boris.unibe.ch/id/eprint/149387

Actions (login required)

Edit item Edit item
Provide Feedback